Trial Profile
A Phase I Clinical Trial for the Treatment of ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Beta-globin-transduced bone marrow cells (Primary) ; Busulfan; Filgrastim
- Indications Beta-thalassaemia
- Focus Adverse reactions
- 11 Jul 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 11 Jul 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.
- 01 Aug 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.